{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T11:24:49Z","timestamp":1784114689001,"version":"3.55.0"},"reference-count":32,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,6,1]],"date-time":"2017-06-01T00:00:00Z","timestamp":1496275200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"The Grand Challenges Saving Lives at Birth","award":["0167-03"],"award-info":[{"award-number":["0167-03"]}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2017,6]]},"DOI":"10.1016\/j.ejps.2017.04.010","type":"journal-article","created":{"date-parts":[[2017,4,20]],"date-time":"2017-04-20T21:01:19Z","timestamp":1492722079000},"page":"382-392","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Preformulation studies of ceftriaxone for pediatric non-parenteral administration as an alternative to existing injectable formulations"],"prefix":"10.1016","volume":"104","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0541-6684","authenticated-orcid":false,"given":"Tina","family":"Kauss","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathieu","family":"Marchivie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thida","family":"Phoeung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Gaubert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Am\u00e9lie","family":"D\u00e9sir\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Tonelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chantal","family":"Boyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-H\u00e9l\u00e8ne","family":"Langlois","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"Cartwright","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melba","family":"Gomes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas","family":"White","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Gaudin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejps.2017.04.010_bb0005","doi-asserted-by":"crossref","first-page":"448","DOI":"10.3109\/10717540903334959","article-title":"Formulation and in vitro evaluation of a PEGylated microscopic lipospheres delivery system for ceftriaxone sodium","volume":"16","author":"Attama","year":"2009","journal-title":"Drug Deliv."},{"key":"10.1016\/j.ejps.2017.04.010_bb0010","doi-asserted-by":"crossref","first-page":"e609","DOI":"10.1542\/peds.2008-3080","article-title":"Intravenous ceftriaxone and calcium in the neonate: assessing the risk for cardiopulmonary","volume":"123","author":"Bradley","year":"2009","journal-title":"Pediatrics"},{"issue":"5","key":"10.1016\/j.ejps.2017.04.010_bb0015","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1107\/S0021889804014876","article-title":"Powder pattern indexing with the dichotomy method","volume":"37","author":"Boultif","year":"2004","journal-title":"J. Appl. Crystallogr."},{"key":"10.1016\/j.ejps.2017.04.010_bb0020","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1002\/jps.10563","article-title":"Enhanced oral bioavailability of poorly absorbed drugs. I. Screening of absorption carrier for the ceftriaxone complex","volume":"93","author":"Cho","year":"2004","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejps.2017.04.010_bb0025","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1002\/jssc.200301306","article-title":"Stability of ceftriaxone in water and cerebrospinal fluid determined by high-performance liquid chromatography","volume":"26","author":"de Diego Glaria","year":"2003","journal-title":"J. Sep. Sci."},{"key":"10.1016\/j.ejps.2017.04.010_bb0030","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1093\/jaoac\/88.2.436","article-title":"Determination of ceftriaxone in cerebrospinal fluid by ion-pair liquid chromatography","volume":"88","author":"de Diego Glaria","year":"2005","journal-title":"J. AOAC Int."},{"key":"10.1016\/j.ejps.2017.04.010_bb0035","doi-asserted-by":"crossref","first-page":"335","DOI":"10.4067\/S0717-97072010000300013","article-title":"Chemical stability of ceftriaxone by a validated stability-indicating liquid chromatographic method","volume":"55","author":"de Diego Glaria","year":"2010","journal-title":"J. Chil. Chem. Soc."},{"key":"10.1016\/j.ejps.2017.04.010_bb0040","series-title":"Patent no. US20090123537 A1","article-title":"Oral dosage form of ceftriaxone and methods of use","author":"Debrouse","year":"2009"},{"key":"10.1016\/j.ejps.2017.04.010_bb0045","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s40272-016-0197-x","article-title":"Ceftriaxone-associated biliary and cardiopulmonary adverse events in neonates: a systematic review of the literature","volume":"19","author":"Donnelly","year":"2017","journal-title":"Pediatr. Drugs"},{"issue":"3","key":"10.1016\/j.ejps.2017.04.010_bb0050","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.ijantimicag.2013.11.006","article-title":"Dose optimisation of antibiotics in children: application of pharmacokinetics\/pharmacodynamics in paediatrics","volume":"43","author":"Downes","year":"2014","journal-title":"Int. J. Antimicrob. Agents"},{"key":"10.1016\/j.ejps.2017.04.010_bb0055","author":"European Pharmacopoeia 9.0"},{"issue":"9","key":"10.1016\/j.ejps.2017.04.010_bb0060","first-page":"1237","article-title":"Pharmacokinetics and clinical evaluation of ceftriaxone in neonates","volume":"41","author":"Fujii","year":"1988","journal-title":"Jpn. J. Antibiot."},{"issue":"7","key":"10.1016\/j.ejps.2017.04.010_bb0065","article-title":"In vitro ceftriaxone stability at new-borns' rectal pH assessed by UV and HPLC methods","volume":"6","author":"Gaudin","year":"2015","journal-title":"Pharm. Anal. Acta"},{"issue":"2","key":"10.1016\/j.ejps.2017.04.010_bb0070","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1185\/03007990903432900","article-title":"Safety and pharmacokinetics of subcutaneous ceftriaxone administered with or without recombinant human hyaluronidase (rHuPH20) versus intravenous ceftriaxone administration in adult volunteers","volume":"26","author":"Harb","year":"2010","journal-title":"Curr. Med. Res. Opin."},{"issue":"2","key":"10.1016\/j.ejps.2017.04.010_bb0075","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1128\/AAC.40.2.485","article-title":"Investigation of bioequivalence and tolerability of intramuscular ceftriaxone injections by using 1% lidocaine, buffered lidocaine, and sterile water diluents","volume":"40","author":"Hayward","year":"1996","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejps.2017.04.010_bb0080","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1023\/A:1018927118863","article-title":"Drug binding by reservoirs in elastomeric infusion devices","volume":"11","author":"Jenke","year":"1994","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejps.2017.04.010_bb0085","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1154\/1.2135315","article-title":"Whole powder pattern decomposition methods and applications: a retrospective","volume":"20","author":"Le Bail","year":"2005","journal-title":"Powder Diffract."},{"key":"10.1016\/j.ejps.2017.04.010_bb0090","doi-asserted-by":"crossref","first-page":"2541","DOI":"10.1002\/jps.20478","article-title":"Cationic analog of deoxycholate as an oral delivery carrier for ceftriaxone","volume":"94","author":"Lee","year":"2005","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejps.2017.04.010_bb0095","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1128\/AAC.50.5.1869-1871.2006","article-title":"Pharmacokinetics of a new, orally available ceftriaxone formulation in physical complexation with a cationic analogue of bile acid in rats","volume":"50","author":"Lee","year":"2006","journal-title":"Antimicrob. Agents Chemother."},{"issue":"10","key":"10.1016\/j.ejps.2017.04.010_bb0100","doi-asserted-by":"crossref","first-page":"2660","DOI":"10.1007\/s11095-012-0782-9","article-title":"Impact of excipient interactions on solid dosage form stability","volume":"29","author":"Narang","year":"2012","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejps.2017.04.010_bb0105","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1080\/03639040701360876","article-title":"Preparation and evaluation of mucin-gelatin mucoadhesive microspheres for rectal delivery of ceftriaxone sodium","volume":"33","author":"Ofokansi","year":"2007","journal-title":"Drug Dev. Ind. Pharm."},{"key":"10.1016\/j.ejps.2017.04.010_bb0110","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/s40204-016-0051-9","article-title":"Development and evaluation of a calcium alginate based oral ceftriaxone sodium formulation","volume":"5","author":"Patel","year":"2016","journal-title":"Prog. Biomater."},{"issue":"5","key":"10.1016\/j.ejps.2017.04.010_bb0115","first-page":"345","article-title":"Crystallographic computing system JANA2006: general features","volume":"229","author":"Petricek","year":"2014","journal-title":"Z. Krist."},{"key":"10.1016\/j.ejps.2017.04.010_bb0120","series-title":"Safety Data Sheet: Ceftriaxone Sodium","author":"Roche","year":"2006"},{"key":"10.1016\/j.ejps.2017.04.010_bb1000","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/0921-4526(93)90108-I","article-title":"Recent Advances in Magnetic Structure Determination by Neutron Powder Diffraction","volume":"192","author":"Rodr\u00edguez-Carvajal","year":"1993","journal-title":"Phys. B"},{"key":"10.1016\/j.ejps.2017.04.010_bb0125","first-page":"142","article-title":"Pharmacokinetics of ceftriaxone in healthy and mastitic goats with special reference to its interaction with polyherbal drug (fibrosin)","volume":"4","author":"Sar","year":"2006","journal-title":"Int. J. Appl. Res. Vet. Med."},{"key":"10.1016\/j.ejps.2017.04.010_bb0130","author":"Theriaque"},{"key":"10.1016\/j.ejps.2017.04.010_bb0135","series-title":"Meeting Report, Geneva, 30th September\u20131st October 2002","article-title":"Explore simplified antimicrobial regimens for the treatment of neonatal sepsis","author":"World Health Organization","year":"2003"},{"issue":"2","key":"10.1016\/j.ejps.2017.04.010_bb0140","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1159\/000238564","article-title":"Treatment of neonatal sepsis with ceftriaxone\/gentamicin and with azlocillin\/gentamicin: a clinical comparison of efficacy and tolerability","volume":"34","author":"Wiese","year":"1988","journal-title":"Chemotherapy"},{"key":"10.1016\/j.ejps.2017.04.010_bb0145","first-page":"35","article-title":"Mechanism of ceftriaxone degradation in aqueous solution","volume":"55","author":"Zajac","year":"1998","journal-title":"Acta Pol. Pharm. Drug Res."},{"key":"10.1016\/j.ejps.2017.04.010_bb0150","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1021\/je0501989","article-title":"Solubility of ceftriaxone disodium in acetone, methanol, ethanol, N,N-dimethylformamide, and formamide between 278 and 318K","volume":"50","author":"Zhang","year":"2005","journal-title":"J. Chem. Eng. Data"},{"key":"10.1016\/j.ejps.2017.04.010_bb0155","doi-asserted-by":"crossref","first-page":"7057","DOI":"10.1021\/ie050210q","article-title":"Non-isothermal dehydration kinetics of ceftriaxone disodium hemiheptahydrate","volume":"44","author":"Zhang","year":"2005","journal-title":"Ind. Eng. Chem. Res."}],"container-title":["European Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S092809871730204X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S092809871730204X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,10,6]],"date-time":"2020-10-06T00:40:50Z","timestamp":1601944850000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S092809871730204X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6]]},"references-count":32,"alternative-id":["S092809871730204X"],"URL":"https:\/\/doi.org\/10.1016\/j.ejps.2017.04.010","relation":{},"ISSN":["0928-0987"],"issn-type":[{"value":"0928-0987","type":"print"}],"subject":[],"published":{"date-parts":[[2017,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Preformulation studies of ceftriaxone for pediatric non-parenteral administration as an alternative to existing injectable formulations","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmaceutical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejps.2017.04.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}